Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre.

Presentación del tema: "Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre."— Transcripción de la presentación:

1 Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort  L.E. López-Cortés, B. Almirante, M. Cuenca-Estrella, J. Garnacho-Montero, B. Padilla, M. Puig-Asensio, I. Ruiz-Camps, J. Rodríguez- Baño B. Padilla, P. Muñoz, J. Guinea, J.R. Paño Pardo, J. García-Rodríguez, C. García Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B. Pérez Gorricho, M. Alonso, F. Sanz Sanz, J. María Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J.E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I. Sánchez Romero, O. Zaragoza, M. Cuenca-Estrella, J. Rodríguez-Baño, A.I. Suarez, A. Loza, A.I. Aller García, E. Martín-Mazuelos, M.R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F.L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J.J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernáez, G. Ezpeleta, E. Bereciartua, J.L. Hernández Almaraz, M. Montejo, R.A. Rivas, R. Ayarza, A.M. Planes, I. Ruiz Camps, B. Almirante, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martinez-Montauti, M. Sierra, J.P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, M. Valerio, A. Díaz-Martín, F. Puchades, A. Mularoni L.E. López-Cortés, B. Almirante, M. Cuenca-Estrella, J. Garnacho- Montero, B. Padilla, M. Puig-Asensio, I. Ruiz-Camps, J. Rodríguez-Baño B. Padilla, P. Muñoz, J. Guinea, J.R. Paño Pardo, J. García- Rodríguez, C. García Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B. Pérez Gorricho, M. Alonso, F. Sanz Sanz, J. María Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J.E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I. Sánchez Romero, O. Zaragoza, M. Cuenca-Estrella, J. Rodríguez-Baño, A.I. Suarez, A. Loza, A.I. Aller García, E. Martín-Mazuelos, M.R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F.L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J.J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernáez, G. Ezpeleta, E. Bereciartua, J.L. Hernández Almaraz, M. Montejo, R.A. Rivas, R. Ayarza, A.M. Planes, I. Ruiz Camps, B. Almirante, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martinez-Montauti, M. Sierra, J.P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, M. Valerio, A. Díaz-Martín, F. Puchades, A. Mularoni  Clinical Microbiology and Infection  Volume 22, Issue 8, Pages 733.e1-733.e8 (August 2016) DOI: /j.cmi Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2 Fig. 1 Flowchart of cases included in empirical therapy cohort (ETC) and targeted therapy cohort (TTC). BSI = bloodstream infection. Clinical Microbiology and Infection  , 733.e1-733.e8DOI: ( /j.cmi ) Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3 Fig. 2 Kaplan-Meier curves for 30-day mortality according to therapy in empirical (A) and targeted (B) therapy cohorts. Clinical Microbiology and Infection  , 733.e1-733.e8DOI: ( /j.cmi ) Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4 Fig. 3 Thirty-day mortality (percentage of treated cases) stratified according to propensity score quartile for receiving echinocandin (Q1, Q2, Q3 and Q4) for empirical therapy (A) and targeted treatment (B). Data in tables are number of deaths/number of treated (percentage). Clinical Microbiology and Infection  , 733.e1-733.e8DOI: ( /j.cmi ) Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions